Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Cannabidiol for Individuals at Risk for Alzheimer's Disease: A Randomized Placebo Controlled Trial
Authors not listed
University of Colorado, Denver · 2024
Abstract
This is a double-blind, randomized controlled trial designed to test the effects of cannabidiol (CBD) on validated biomarkers of Alzheimer's disease (AD) progression, and behavioral, neurocognitive, and clinical measures, with putative mechanisms of action.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-11 MST
Cite this
APA
Anonymous. (2024). Cannabidiol for Individuals at Risk for Alzheimer's Disease: A Randomized Placebo Controlled Trial. <em>University of Colorado, Denver</em>. https://clinicaltrials.gov/study/NCT05822362
Vancouver
Anonymous. Cannabidiol for Individuals at Risk for Alzheimer's Disease: A Randomized Placebo Controlled Trial. University of Colorado, Denver. 2024.
BibTeX
@misc{anon2024Cannab,
title = {Cannabidiol for Individuals at Risk for Alzheimer's Disease: A Randomized Placebo Controlled Trial},
author = {Anonymous},
journal = {University of Colorado, Denver},
year = {2024},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Neurology Office of South Florida 2025
Open access · US-GOV
A Phase II, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Sfatey and Tolerability of X/T+X-EC vs. Placebo in Participants With Alzheimer's Disease Currently Treated With Lecanemab.
Cognition Therapeutics 2023
Open access · US-GOV
Synaptic Therapy Alzheimer's Research Trial (START): A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease Over 18 Months.
Rush University Medical Center 2017
Open access · US-GOV
MIND Diet Intervention to Prevent Alzheimer's Disease
Helse Stavanger HF 2023
Open access · US-GOV
A Randomized, Double-blind, Placebo Controlled, Cross-over Clinical Trial of Acute Safety and Biological Effects of a Polyphenol Supplement
IGC Pharma, LLC 2021
Open access · US-GOV
A Phase I Randomized Placebo Controlled MAD Study to Evaluate Safety and Tolerability of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease
The Lancet 2021
Preprint · OA